Back to
Ms Mariana Ruiz Silva
Research Associate

Ms Mariana Ruiz Silva

BSc, MSc, PhD

Medicine & Health
The Kirby Institute

Mariana graduated in Pharmaceutical and Biological Chemistry from the Universidad Nacional Autonoma de Mexico. She holds a MSc in Medical and Pharmaceutical Drug Innovation from the Rijksuniversiteit Groningen (RUG) in The Netherlands. She received a PhD in virology from the RUG for the study of the innate immune response to dengue and chikungunya virus (co)-infections. After moving to Australia, she worked as a research assistant for NSW Health and UNSW performing whole genome sequencing of SARS-CoV-2. In 2021, Mariana joined the Kirby Institute to investigate the pathogenesis of SARS-CoV-2. She has experience working with viruses in a Biosafety level 3 lab, TIRF microscopy and next-generation sequencing.  
Phone
+61-2-93480776
E-mail
mruizsilva@kirby.unsw.edu.au
Location
Level 5, Wallace Wurth Building, UNSW Sydney NSW 2052
  • Journal articles | 2023
    2023, 'Emergence and antibody evasion of BQ, BA.2.75 and SARS-CoV-2 recombinant sub-lineages in the face of maturing antibody breadth at the population level', eBioMedicine, 90, pp. 104545, http://dx.doi.org/10.1016/j.ebiom.2023.104545
    Journal articles | 2022
    2022, 'Assessment of Inter-Laboratory Differences in SARS-CoV-2 Consensus Genome Assemblies between Public Health Laboratories in Australia', Viruses, 14, pp. 185 - 185, http://dx.doi.org/10.3390/v14020185
    Journal articles | 2022
    2022, 'Platform for isolation and characterization of SARS-CoV-2 variants enables rapid characterization of Omicron in Australia', Nature Microbiology, 7, pp. 896 - 908, http://dx.doi.org/10.1038/s41564-022-01135-7
    Journal articles | 2022
    2022, 'SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern', eBioMedicine, 84, pp. 104270, http://dx.doi.org/10.1016/j.ebiom.2022.104270
    Journal articles | 2020
    2020, 'TLR2 on blood monocytes senses dengue virus infection and its expression correlates with disease pathogenesis', Nature Communications, 11, http://dx.doi.org/10.1038/s41467-020-16849-7
    Journal articles | 2017
    2017, 'Suppression of chikungunya virus replication and differential innate responses of human peripheral blood mononuclear cells during co-infection with dengue virus', PLoS Neglected Tropical Diseases, 11, http://dx.doi.org/10.1371/journal.pntd.0005712
    Journal articles | 2016
    2016, 'Mechanism and role of MCP-1 upregulation upon chikungunya virus infection in human peripheral blood mononuclear cells', Scientific Reports, 6, http://dx.doi.org/10.1038/srep32288
    Journal articles | 2014
    2014, 'Rabbit monoclonal antibodies directed at the T3SS effector protein YopM identify human pathogenic Yersinia isolates', International Journal of Medical Microbiology, 304, pp. 444 - 451, http://dx.doi.org/10.1016/j.ijmm.2014.02.003
    Journal articles | 2012
    2012, 'Delaying aging and the aging-associated decline in protein homeostasis by inhibition of tryptophan degradation', Proceedings of the National Academy of Sciences of the United States of America, 109, pp. 14912 - 14917, http://dx.doi.org/10.1073/pnas.1203083109
  • Preprints | 2022
    2022, Rapid isolation and resolution immune evasion and viral fitness across contemporary SARS-CoV-2 variants, , http://dx.doi.org/10.21203/rs.3.rs-1210846/v1
    Preprints | 2020
    2020, Rewiring PBMC responses to prevent CHIKV infection-specific monocyte subset redistribution and cytokine responses, , http://dx.doi.org/10.1101/2020.06.04.132340

2016 Jan Kornelis de Cock Foundation Grant

2010 Mexican National Council for Science and Technology (CONACyT) Scholarship

2010 Medical and Pharmaceutical Drug Innovation (MPDI) Scholarship

SARS-CoV-2 pathogenesis